Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 12/20 | 0.83 |
| ▸ | TYMS known ✓ | P04818 | 6/20 | 0.83 |
| ▸ | GART known ✓ | P22102 | 2/20 | 0.73 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.73 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.73 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 0.73 |
| ▸ | ATIC | P31939 | 2/20 | 0.73 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.73 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.73 |
| ▸ | FRK | P42685 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL12022769 | 1.00 | DHFR (0.83) | DHFRTYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL9227108 | 0.96 | DHFR (0.78) | DHFRTYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL9227343 | 0.96 | DHFR (0.78) | DHFRTYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL8997255 | 0.95 | DHFR (0.75) | DHFRTYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL8997171 | 0.95 | DHFR (0.75) | DHFRTYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL7848195 | 0.92 | DHFR (0.84) | DHFRTYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL9564226 | 0.92 | DHFR (0.73) | DHFRTYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL9223619 | 0.91 | DHFR (0.70) | DHFRTYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL14331358 | 0.91 | DHFR (0.72) | DHFRTYMSFOLR1SLC19A1SLC46A1 | |
| SCHEMBL9227129 | 0.89 | DHFR (0.67) | DHFRTYMSFOLR1SLC19A1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133727-A1 | COMBINATION THERAPIES FOR USE IN TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2022-05-05 | — | — | US | disclosed |
| WO-2022036067-A1 | COMBINATION THERAPIES FOR USE IN TREATING CANCER | SERVIER PHARMACEUTICALS, LLC (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3923950-A1 | COMBINATION THERAPIES FOR USE IN TREATING CANCER | Les Laboratoires Servier SAS (FR) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020168032-A1 | COMBINATION THERAPIES FOR USE IN TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-9789113-B2 | Pemetrexed dipotassium formulations | SHILPA MEDICARE LIMITED | 2017-10-17 | — | — | US | disclosed |
| US-20170100403-A1 | PEMETREXED DIPOTASSIUM FORMULATIONS | SHILPA MEDICARE LIMITED (IN) | 2017-04-13 | — | — | US | disclosed |
| US-9174991-B2 | Crystalline form of pemetrexed disodium | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9174991-B2 | Crystalline form of pemetrexed disodium | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-8981090-B2 | Process for the synthesis of pemetrexed disodium salt | CHEMI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-8981090-B2 | Process for the synthesis of pemetrexed disodium salt | CHEMI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-20120329819-A1 | NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | UNIVERSITY OF ZURICH (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120172595-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF PEMETREXED DISODIUM SALT | CHEMI S.P.A. (IT) | 2012-07-05 | — | — | US | disclosed |
| US-20120172595-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF PEMETREXED DISODIUM SALT | CHEMI S.P.A. (IT) | 2012-07-05 | — | — | US | disclosed |
| EP-2213674-A1 | PURIFICATION METHOD OF PEMETREXED SALTS,SODIUM SALTS AND DISODIUM SALTS | Chongqing Pharmaceutical Research Institute Co., Ltd. (CN) | 2010-08-04 | — | — | EP | disclosed |
| EP-1105396-A1 | PROCESS FOR THE PREPARATION OF PYRROLO[2,3-D]PYRIMIDINES | The Trustees of Princeton University (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6066732-A | Process for the preparation of pyrrolo[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| WO-2000011004-A1 | PROCESS FOR THE PREPARATION OF PYRROLO[2,3-D]PYRIMIDINES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0549886-B1 | Process for the preparation of pyrrolo[2,3-d]pyrimidines | UNIV PRINCETON (US) | 1996-10-30 | — | — | EP | disclosed |
| US-5254687-A | Process for the preparation of pyrrolo[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0549886-A1 | Process for the preparation of pyrrolo[2,3-d]pyrimidines | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1993-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329819-A1 | NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | TYMP, TYMS, MTHFD1 | DHFR 11/4885TYMS 2/4885GART 149/4885 |
| US-20120172595-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF PEMETREXED DISODIUM SALT | PCNA, POLH, TYMP | DHFR 51/4885TYMS 6/4885GART 113/4885 |
| US-20220133727-A1 | COMBINATION THERAPIES FOR USE IN TREATING CANCER | DCTPP1, XPOT, XPO1 | DHFR 2041/4885TYMS 67/4885GART 1541/4885 |
| US-20170100403-A1 | PEMETREXED DIPOTASSIUM FORMULATIONS | TYMP, DPYD, TYMS | DHFR 44/4885TYMS 3/4885GART 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.